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Gag (p17)We have constructed stable virus-like particles displaying the HIV-1 Gag(p17) protein as an N-terminal
fusion with an engineered protein domain from the Geobacillus stearothermophilus pyruvate dehydrogenase
subunit E2. Mice immunized with the Gag(p17)-E2 60-mer scaffold particles mounted a strong and
sustained antibody response. Antibodies directed to Gag(p17) were boosted signiﬁcantly with additional
immunizations, while anti-E2 responses reached a plateau. The isotype of the induced antibodies was biased
towards IgG1, and the E2-primed CD4+ T cells did not secrete IFNγ. Using transgenic mouse model systems,
we demonstrated that CD8+ T cells primed with E2 particles were able to exert lytic activity and produce
IFNγ. These results show that the E2 scaffold represents a powerful vaccine delivery system for whole
antigenic proteins or polyepitope engineered proteins, evoking antibody production and antigen speciﬁc CTL
activity even in the absence of IFNγ-producing CD4+ T cells.istry, C.N.R., Via P. Castellino
ardinis).
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After 25 years of HIV research and several failed vaccine trials
(Buchbinder et al., 2008), despite some evidence for modest vaccine
protection in humans (Rerks-Ngarm et al., 2009), new vaccine
modalities are still needed to elicit the high-titer and durable immune
responses. These responses include, but may not be limited to,
cytotoxic T cells (CTL) directed to multiple viral proteins, strong T
helper responses, and neutralizing antibodies (NAbs) that are
effective against a broad range of primary HIV-1 isolates. Proof-of-
principle experiments in nonhuman primate challenge models have
been useful in understanding the role of antibodies in blocking
infection, when they are present at sufﬁcient titers in advance of
exposure (Baba et al., 2000; Hessell et al., 2009; Hessell et al.; Mascolaet al., 2000; Shibata et al., 1999). Similarly, the presence of T cell
responses is correlated with viral control, as shown by T cell depletion
studies in nonhuman primates (Lifson et al., 2001; Schmitz et al.,
2005) and protection from disease when strong T cell responses are
induced by vaccination with recombinant viral vectors (Hansen et al.,
2009; Santra et al., 2005). Efforts have thus been focused on designing
vaccines and delivery systems that can elicit strong, durable immunity
that is directed against multiple viral antigens, to prevent ready
escape. Current methods for eliciting T-cell responses for HIV, in
particular, have presented limitations due to poor immunogenicity
that is limited in seropositive individuals (O'Brien et al., 2009).
However, in the case of some vectors, such as adenovirus, strategies
have been proposed to circumvent anti-vector immunity (Roberts et
al., 2006). Moreover, combining two or more vaccine modalities in
“prime-boost” regimens can elicit stronger immune responses than
either vaccine alone (Kibuuka et al., 2010; Koup et al., 2010; Rerks-
Ngarm et al., 2009).
The inactivated HIV virion itself has long been considered as a
vaccine candidate and this approach, especially for therapeutic
vaccines, was championed by polio vaccine luminary Jonas Salk
(Salk, 1987). Protective efﬁcacy with formalin-inactivated SIV in
nonhuman primates was demonstrated (Johnson et al., 1992;
Murphey-Corb et al., 1990) but the vaccine was complicated by the
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protection-unrelated to the SIV antigens (Arthur et al., 1995; Stott,
1991). Recent advances in understanding of virus assembly have led
to the development of methods that chemically and irreversibly
inactivate whole virions and that maintain the receptor binding
activity of Envelope (Arthur et al., 1998; Lifson et al., 2004). The
attractiveness of VLPs that can mimic the natural HIV virion without
any risk of HIV infection led to the early development of recombinant
Gag-Env particles produced in mammalian cells by recombinant
vaccinia virus (Haffar et al., 1990, 1991, 1992; Luo et al., 2003), or
rhinovirus chimeras (Arnold et al., 1994; Lapelosa et al., 2010), yeast
(Tsunetsugu-Yokota et al., 2003), or in other systems, reviewed in
(Deml et al., 2005). While clearly immunogenic in eliciting Gag-
speciﬁc CTL (Paliard et al., 2000) and antibodies, including some
neutralizing antibodies (Ding et al., 2002), none of these approaches
has elicited strong protective immunity. Explanations for low level
immunogenicity may include dose, stochiometry of key immunogens
such as Envelope (when present), or delivery or adjuvant systems
employed to date.
We have previously designed and investigated a new delivery
vehicle in which antigenic determinants are inserted on the surface of
an icosahedral scaffold formed by the acyltransferase component (E2
protein) of the multienzyme pyruvate dehydrogenase complex (PDH)
from Geobacillus stearothermophilus, and reported the ability of this
scaffold to display peptides in a high immunogenic form (De
Berardinis et al., 2003; Domingo et al., 2003). The core C-terminal
catalytic domain of E2 self-assembles into trimers, which in turn
aggregate to generate a 60-chain core with icosahedral symmetry
(Domingo et al., 2001; Henderson et al., 1979; Perham, 2000).
Moreover this 60-meric icosahedral structure can be regeneratedwith
high efﬁciency from denaturing conditions in vitro, without the need
of chaperonins (Allen and Perham, 1997; Lessard et al., 1998). The
robustness of this peptide based virus-like particle has rendered it an
attractive macromolecular scaffold for presentation of exogenous
molecules on its surface (De Berardinis et al., 2003; Domingo et al.,
2001, 2003) and for molecular encapsulation in its cavity (Dalmau et
al., 2008, 2009a,b). Efﬁcient refolding of E2 to the 60-mer is also
possible with foreign peptides replacing the natural peripheral
domains, as N-terminal fusions to the core domain. Thus, a suitably
engineered E2 core (E2DISP) can display 60 copies of heterologousA
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Fig. 1. Schematic representation of E2 constructs. (A) p17-Gag protein or OVA323–339, OVA2
(p17)-OVA257–264-E2 fusion protein the OVA257–264 epitope is inserted between the Gag(p17
60-mer E2 complexes. pep23E2/Gag(p17)-E2 hybrid particles express simultaneously Gag(peptides on the surface of a high molecular mass scaffold (De
Berardinis et al., 2003; Domingo et al., 2001, 2003). This property can
be exploited for vaccine design. Here we further expanded the
delivery properties of the E2 scaffold by displaying a whole protein at
the surface of the scaffold, and analyzed the in vivo induction of B and
T cell responses.
Results
Construction of E2 particles
We constructed OVA257–264E2 and OVA323–339E2 particles expres-
sing the OVA peptides at the N-terminus of E2. We also constructed
Gag(p17)-E2, and Gag(p17)-OVA257–264-E2 particles respectively
expressing the HIV-1 Gag-p17 protein at the N-terminus of E2 or, in
addition, the OVA257–264 peptide between the E2 carrier protein and
the HIV-1 Gag(p17) protein. Both the Gag(p17)-E2 and Gag(p17)-
OVA257–264-E2 fusion proteins also assembled into 24 nm virus-like E2
particles expressing up to 60 copies of the HIV-1 Gag(p17) or Gag
(p17)-OVA257–264 antigens on their surface (see Fig. 1). Hybrid
particles displaying equimolar amounts of pep23E2 and Gag(p17)-
E2 particles which co-express a strong T helper epitope from HIV-1
reverse transcriptase were also generated (Fig. 1) according to
previously described methodologies (Domingo et al., 2003). Correct
folding of these particles was demonstrated by gel ﬁltration
chromatography to conﬁrm size and electron microscopy analysis
(data not shown).
Generation of Gag(p17) speciﬁc CTLs
To investigate the ability of Gag(p17)-E2 particles to elicit peptide-
speciﬁc CTL responses in vivo, HHD (HLA-A2.1/H2-Db) transgenic
mice were immunized with double-display pep23E2/Gag(p17)-E2
particles and the generation of CTLs speciﬁc for the HLA-A2 restricted
Gag(p17) epitope SLYNTVATL was examined. Since we previously
reported that in the HHD mouse model the immunization with E2
particles co-expressing helper and cytotoxic T cell epitopes is a
requirement for inducing a CTL response, we used the pep23E2/Gag
(p17)-E2 particles co-expressing the pep23 helper epitope to ensure
strong T cell help in these mice (Domingo et al., 2003). Splenocytes  
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for 5 days with syngeneic LPS-induced blast cells pulsed with the
same E2 particles used for immunization. Effector cell-mediated
cytotoxic activities were tested in 51Cr release assays towards RMA-S-
HHD (Tap-, HLA-A2.1+) target cells loaded with the Gag(p17)
SLYNTVATL synthetic peptide. As shown in Fig. 2A, speciﬁc cytotoxicA
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Fig. 2.Humoral and cytotoxic response induced by Gag(p17)-E2 particles. (A) Cytotoxic
response of splenocytes from HHD mice immunized twice in the absence of adjuvants
with pep23E2/Gag(p17)-E2 (black bars) or E2wt (gray bars), and challenged after in
vitro restimulation against RMA-S HHD target cells prepulsed with SLYNTVATL peptide.
The percentage of antigen speciﬁc killing is shown on y-axis after subtraction of
background killing of unpulsed targets and represents the mean±SD of cytotoxic
activity of ﬁve mice in each group. Effector/target ratios are shown on the x-axis. (B)
BALB/cxC57BL/6 F1 mice were immunized with Gag(p17)-E2 (squares), pep23E2/Gag
(p17)-E2 (triangles) or E2wt (circles) particles at weeks 0 and 4 (arrows). On weeks 2,
6 and 30, mice were bled and sera were analyzed by ELISA for Gag-speciﬁc total IgG
endpoint titers. Figure represents the media±SD of total IgG titer of nine mice in each
group. (C) Production of anti Gag isotypes in mice immunized twice with Gag(p17)-E2
in presence of IFA, CpG, or without adjuvant. Immunization with vaccinia virus Gag
(rVV-Gag) was also performed as control of the isotype IgG2a induction. The values
represent the mean±SD of nine mice in each group; *Pb0.01, **Pb0.05.activities were generated in splenocytes isolated from mice
immunized (in the absence of adjuvants) with pep23E2/Gag
(p17)-E2 particles. This response was similar in mice immunized
in the presence of adjuvant (data not shown). In contrast, no
cytotoxic activity was found in splenocytes isolated from mice
immunized with E2 wt particles (Fig. 2A). Splenocytes isolated from
unimmunized mice and restimulated in vitro with pep23E2/Gag
(p17)-E2 particles-pulsed LPS-blasts did not exert cytotoxic activity
(data not shown).
Induction of anti-Gag(p17) antibodies
We measured total IgG titers against Gag and E2 proteins in the
sera of mice (three groups of three mice each) bled after one or two
doses of Gag(p17)-E2, pep23E2/Gag(p17)-E2 or E2 wt particles,
which were administered s.c. either in the presence or in the absence
of adjuvants. The IgG antibodies against Gag were scarcely detectable
after one dose but were strongly evident after two doses (Fig. 2B). No
differences were observed between groups of mice immunized with
particles displaying Gag(p17) alone or hybrid particles displaying
pep23E2/Gag(p17)-E2 particles (Fig. 2B). Antibodies directed against
E2 were detectable after one dose and boosted by the second dose
(not shown). The high titer of antibodies persisted for 30 weeks
(Fig. 2B). IgG isotype was signiﬁcantly biased in favor of IgG1 as
compared to the response obtained in mice immunized with vaccinia
Gag used as a control (Fig. 2C). The antibody production was similar
in the sera of mice immunized in the absence or in the presence of
IFA or CpG adjuvants (Fig. 2C). In separate experiments, we
immunized C57BL6xBALB/c mice three times (weeks 0, 4, and 31)
with Gag(p17)-E2 alone; E2-speciﬁc responses were not further
enhanced by the third immunization, while the Gag-speciﬁc
responses increased signiﬁcantly with the third dose (data not
shown).
We conclude that: 1) the HIV-1 Gag(p17) protein displayed on Gag
(p17)-E2 particles is strongly immunogenic in the absence of
adjuvant; 2) responses to Gag are primed by one dose and boosted
with a second or third dose; 3) antibodies level persisted for many
weeks, at least 27 weeks; 4) although responses to E2 increase with a
boosting dose, this does not abrogate the boosting effect for Gag
responses; and 5) co-expression on E2 of exogenous helper epitopes
is not needed for antibody production in the immunized mice.
Role of CD4+ T cells in IgG1 induction
In order to analyze the role of CD4+ T cell help in the induction of
an antibody response characterized by the IgG1 isotype, we assessed
the production of IFNγ in CD4+ T cells isolated from C57BL/6xBALB/c
(MHC H-2bd) F1 mice immunized with Gag(p17)-E2, and stimulated
with overlapping peptides (15 amino acid residue length) encom-
passing the Gag(p17) sequence. The CD4+ T cells from mice
immunized with one or two doses of Gag(p17)-E2 particles did not
produce IFNγ upon restimulation with 15-mer Gag peptides (data not
shown). This result may be consistent with the lack of T helper
epitopes restricted bymouseMHCH-2bd in the Gag(p17) sequence, as
these epitopes are not reported in the NIH database. Thus, in order to
assess the role of CD4+ T cell help in the induction of antibodies with
the IgG1 isotype, we chose to study the response to a well-established
epitope such as the MHC H-2b-restricted chicken ovalbumin 323–339
(OVA323–339) epitope. For this study we used OVA323–339E2 particles
and the OT-II mice which have CD4+ T cells expressing a transgenic
TCR speciﬁc for the OVA323–339 epitope. According to established
protocols (Parish et al., 2009) we thus transferred 3×106 CFSE-
labeled, OVA323–339-speciﬁc, CD4+ OT-II T cells into C57BL/6 (MHC
IAb) recipient mice. The day after, mice were immunized either s.c.
with 100 μg of E2 particles displaying the OVA323–339 peptide, or i.p.
with 500 μg of soluble ovalbumin plus poly(I:C). As control,
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Fig. 3. Priming of OT-II cells with E2 particles. C57BL/6 recipient mice (ﬁve per group) of CFSE-labeled OT-II T cells were immunized with E2wt particles, OVA323–339 E2 particles or
soluble ovalbumin (OVA) plus poly (I:C) or PBS. 3 days after immunization, mice were sacriﬁced and the spleen cells analyzed by ﬂow cytometry for CFSE content (A–B), or
restimulated in vitro with OVA323–339 synthetic peptide for IFNγ production analysis (C–D). (A) Figure shows data from a single representative mouse for each group. Proﬁles are
gated on Vα2+ CD4+ cells. (B) Mean values of all mice in each group. Bars represent mean±SD of percentage values of CFSE-labeled proliferating cells obtained in three
independent experiments; *Pb0.01. (C) IFNγ production of CD4+ gated cells. The percentages of IFNγ positive cells are indicated in the upper right corners. Figure shows data from a
single representative mouse for each group. (D) Data of IFNγ production by CD4+ T cells from all immunized mice. Bars represent mean±SD of values obtained in three
independent experiments.
299A. Caivano et al. / Virology 407 (2010) 296–305immunization with E2 wt particles was also performed. After 3 days,
isolated splenocytes were evaluated for OT-II proliferation as assayed
by CFSE dilution, and the results illustrated in Fig. 3A–B show a strong
proliferative response of OT-II CD4+ T cells in OVA323–339E2 treated
mice as compared to the proliferative response observed in mice
which received soluble OVA plus poly(I:C). We also measured IFNγ
production by intracellular staining of splenocytes. As illustrated in
Fig. 3C–D, CD4+ OT-II cells did not produce IFNγ upon restimulation
with the OVA323–339 synthetic peptide. Nonspeciﬁc stimulation with
PMA plus ionomycin gave rise to high levels of IFNγ (data not shown).Priming with E2 particles induces antigen speciﬁc CD8+ T cells able to
produce IFNγ
We also performed a study using the OT-I model characterized by
CD8+ T cells expressing a transgenic TCR able to recognize the CTL
epitope SIINFEKL from chicken ovalbumin residues 257–264
(OVA257–264). In this case we did not use E2 particles co-expressing
the helper epitope pep23 because we previously reported (Del Pozzo
et al., 2010; Mascolo et al., 2007) that co-expression of a helper
epitope in the immunizing particles is not necessary to obtain a
300 A. Caivano et al. / Virology 407 (2010) 296–305CTL response speciﬁc towards the OVA257–264 peptide in C57BL/6
wild type mice. Thus, after the adoptive transfer of CSFE-labeled
OT-I/CD8+ T cells, C57BL/6 recipient mice were immunized with E2
particles expressing the OVA257–264 peptide. After 3 days splenocytes
were isolated from the immunized mice and respectively evaluated
for OT-I proliferation and IFNγ production. As illustrated in Fig. 4A–B,
a speciﬁc proliferation, as assessed by CSFE dilution, was observed
on CD8+ T cells isolated from mice immunized with OVA257–264E2
particles. In contrast to OT-II CD4+ T cells, the OT-I CD8+ T cells were
able to produce IFNγ upon restimulation with the speciﬁc OVA257–264
synthetic peptide (Fig. 4C–D).
Induction of cytotoxic T cells by Gag(p17)-OVA257–264-E2 particles
We thus constructed a fusion protein expressing the OVA257–264
CTL epitope between the E2 carrier and the Gag(p17) protein, and
assessed the production of OVA speciﬁc CTL in C57BL/6 wild type
mice. Aim of this analysis was to demonstrate the ability of E2
particles to be processed and to cross-present the OVA257–264 CTL0
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Fig. 4. Priming of OT-I CD8+ cells and INFγ production. C57BL/6 recipient mice (ﬁve per g
particles or PBS. Three days after immunization, mice were sacriﬁced and the spleen cells ana
synthetic peptide for IFNγ production analysis (C–D). (A) Figure shows data from a single r
values of all mice in each group. Bars represent mean±SD of percentage values of CFSE-lab
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(D) Data of IFNγ production by CD8+ T cells from all immunized mice. Bars represent meaepitope even if it was located in an internal position in comparison
with E2 particles expressing the OVA257–264 peptide as N-terminal
epitope.
C57BL/6 mice (MHC H-2b) were immunized with two subcutane-
ous injections of the Gag(p17)-OVA257–264-E2, OVA257–264-E2 or E2
wild type particles. Two weeks after the second immunization, the
mice were sacriﬁced and the splenocytes were isolated, and
restimulated in vitro with syngeneic LPS-induced blast cells pulsed
with the OVA257–264 peptide. After 7 days, effector cells were tested
for OVA257–264 peptide speciﬁc responses by cytotoxic assay,
pentamer staining and intracellular staining. Fig. 5A shows the
cytotoxic activity of splenocytes isolated from mice immunized with
Gag(p17)-OVA257–264-E2 particles, OVA257–264-E2 orwith E2 particles.
The results indicate that Gag(p17)-OVA257–264-E2 and OVA257–264-E2
particles elicited the induction of OVA257–264 speciﬁc cytotoxic T cells.
Using pentamer staining we further characterized the effector cell
population. As illustrated in Fig. 5B, CD8+ T cells speciﬁcally stained
by the OVA-pentamers-PE (carrying the OVA peptide SIINFEKL), were
present in splenocytes isolated frommice immunized with Gag(p17)-OVA257-264-E2
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Fig. 5. Antigen speciﬁc cytotoxic T cells raised in mice immunized with Gag(p17)-OVA257–264-E2 particles. C57BL/6 mice (ﬁve per group) were immunized twice with Gag(p17)-
OVA257–264-E2, OVA257–264-E2 or E2wt particles. Fourteen days after the second immunization splenocytes were isolated and cultured in vitro for 7 days in the presence of synthetic
OVA257–264 peptide. (A) The cultured cells were used as effector cells in a lytic assay towards EL4 target cells prepulsed with OVA257–264 peptide. The percentages of antigen speciﬁc
killing is shown on y-axis after subtraction of background killing of unpulsed targets and represent the mean±SD of cytotoxic activities of all mice in each group. Data of three
different experiments are reported. Effector/target ratios are shown on the x-axis. (B) Pentamer staining of cultured cells. The dot plots represent ﬂow cytometric analysis of spleen
cells stained with anti-CD8 FITC mAb and either OVA-pentamers-PE carrying the OVA peptide (SIINFEKL) or ctrl-pentamers-PE carrying the control ctrl (SSYSYSSL) peptide. Figure
shows data from a single representative mouse for each group and is representative of at least three different experiments. (C) The percentage of CD8+ cells producing INFγ upon
restimulation with OVA257–264 synthetic peptide is shown in the upper right corner of each plot after intracellular staining and FACS analysis. Figure shows data from a single
representative mouse for each group and is representative of at least three different experiments.
301A. Caivano et al. / Virology 407 (2010) 296–305OVA257–264-E2 or OVA257–264-E2 particles. Furthermore, we also
visualized, by intracellular staining, the production of IFNγ by CD8+
T cells isolated from the immunized mice and restimulated with the
OVA257–264 synthetic peptide (Fig. 5C).
Discussion
We previously described the immunogenicity of small epitopes
(9–15 aa) displayed on the E2 scaffold (De Berardinis et al., 2003;
Domingo et al., 2003). However, larger protein antigens may be more
useful, as they contain multiple T cell epitopes as well as antibody
determinants in their native context. Each E2 chain in the G.
stearothermophilus PDH complex naturally displays, at the N-terminus
of the acyltransferase core domain, 187 amino acid residues in the
form of the two folded protein domains (lipoyl and peripheral subunit
binding) and two ﬂexible linkers. Moreover, the E2 system is naturally
designed to present up to 60 copies of the E1 (~150 kDa) or E3
(~100 kDa) enzymes noncovalently attached on its surface. Thus, in
theory, it is possible that large polypeptides can be attached to the E2
scaffold, which is formed by the acetyltransferase core domain.
In this context, we have expressed on E2 the HIV-1 Gag(p17)
protein. Expression of this protein allowed the correct folding of the
60-mer scaffold. Moreover, Gag(p17) was expressed in a native form
being recognized by a monoclonal antibody speciﬁc for a conforma-
tional epitope of the Gag(p17) protein (De Berardinis and Haigwood,
2004). Here we show the ability of Gag(p17) to induce in vivo a
sustained humoral immune response. In fact, high titers of antibodies
were detected after immunization in the absence of added adjuvants
and the speciﬁc antibodies were still present in mice sera 30 weeks
after the immunizations. The presence of an exogenous T cell help co-
displayed by the E2 particles was not necessary for mice to mount asustained antibody response. This result is in agreement with
previously reported data on antibody production by immunizing
with E2 particles not co-expressing an exogenous helper peptide
(Domingo et al., 2001, 2003). However, we cannot exclude that the
primed mice may recognize MHC H2bd restricted T helper epitope/s
present in the E2 scaffold.
The analysis of IgG subclasses raised in mice sera indicates a bias
towards IgG1 response, suggesting that a Th2-type response (Reiner
and Locksley, 1995) is preferentially induced by E2 antigen delivery.
However, we do not have a direct evidence for the role of E2-mediated
T cell help in the induction of the anti-Gag IgG1 response. Immune
responses in humans against most infections are of mixed pattern or
balanced between Th1 and Th2. The balance needed between the
induction of an effective antibody response versus a T cell response in
protecting against live infection, is not well understood. However, we
can hypothesize that in order to combat speciﬁc pathogens, it may be
advantageous to preferentially induce a Th1 or Th2-type of response.
Moreover, it is known that addition of a different kind of adjuvantmay
shift the immune response towards alternative pathways. In this
context, it is important to assess which type of response is induced by
a particular delivery vehicle in order to use it for eliciting a preferred
pattern of cytokines response. Here we have analyzed the CD4+ T cell
response induced by E2 delivery using the OT-II mouse model. We
observed that the proliferating OT-II CD4+ T cells, primed with E2
particles carrying the OVA323–339 peptide, did not produce IFNγ.
Future work will be addressed to identify the cytokines produced by
the CD4+ T cells upon priming via E2 antigen delivery.
We also studied the CD8+ T cell response in HHD transgenic mice,
in the OT-I model and in C57BL/6 mice. In order to study the response
in HHD mice we used E2 particles co-displaying the helper peptide
pep23 because we previously observed that a CTL response can be
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strong helper epitope (Domingo et al., 2003). On the other hand,
according to previous ﬁndings in another system (Del Pozzo et al.,
2010; Mascolo et al., 2007) we found that that co-expression of the
pep23 helper epitope was not necessary to induce a CD8+ T cell
response against the OVA257–264 antigenic peptide SIINKFEL in OT-I
and in C57BL/6 wild type mice. The data obtained, using the OT-I
model system, show the production of IFNγ by antigen speciﬁc CD8+
T cells. These results are in contrast to data obtainedwith CD4+T cells
in the OT-II model. Moreover, in wild type C57BL/6 mice immunized
with E2 particles carrying the OVA257–264 peptide as a fusion with the
Gag(p17) we also induced antigen-speciﬁc CD8+ cytotoxic T cells
able to produce IFNγ. CTL speciﬁc for the HLA-A2 restricted Gag(p17)
epitope SLYNTVATL were also induced in HHD transgenic mice
immunized with pep23E2/Gag(p17)-E2 particles. It should be
emphasized that in both of these latter constructs the CTL epitopes
were located in an internal position, requiring processing for class I
presentation. This suggests that E2 delivery may be employed to
obtain response towards whole immunogenic proteins or to display
engineered constructs encompassing multiple epitopes. In this
context we have previously observed that E2 particles can reach
both the MHC class I and class II compartments (De Berardinis et al.,
2003).
Vaccines designed to limit or prevent HIV infection are generally
thought to require broad sustained humoral and cellular immune
responses to be effective (Fauci et al., 2008). These types of responses
have been difﬁcult to elicit with existing approaches, even by
combining modalities. Thus, both novel immunogens and more
effective antigen presentation strategies are needed to complement
the existing array of options or to be used in prime-boosting
immunization strategies (Barnett et al., 1997; Doria-Rose et al.,
2003; Law et al., 2007). From these data we can conclude that the Gag
(p17) HIV-1 protein is effectively presented to the immune system by
the E2 scaffold. In immunized mice this scaffold elicits, not only the
production of a sustained humoral response, but also the induction of
cytotoxic T cells. The ability of virus-like particles similar in size to the
E2 scaffold to elicit both types of immunity represents an advantage
over recombinant proteins, which primarily target antibody genera-
tion and viral vectors that are most effective in eliciting cell mediated
responses. In theory, multiple HIV antigens and immune effectors/
adjuvants can be presented on the same scaffold, limited only by steric
constraints and solubility. In this context, the E2 antigen delivery
system, which affords simplicity and safety along with the capability
of inducing sustained humoral and cellular antigen-speciﬁc immune
responses, represents a promising new tool that can be combined
with other approaches to advance the ﬁeld of vaccinology.Materials and methods
Construction of E2 vectors
The OVA257–264-E2, OVA323–339-E2, Gag(p17)-E2 and Gag(p17)-
OVA257–264-E2 vectors were constructed from the previously de-
scribed pETE2DISP (De Berardinis et al., 2003; Domingo et al., 2001,
2003), to allow the expression, as N-terminal fusion to the E2 core
scaffold, of the ovalbumin (OVA) peptides 257–264 and 323–339
(OVA257–264 and OVA323–339), the HIV-1 Gag(p17) protein and the
OVA257–264 peptide fused to the HIV-1 Gag(p17) protein.
Oligonucleotide sequences encoding the OVA peptides sequence
SIINFEKL and ISQAVHAAHAEINEAGR with the protruding ends for
NcoI and XmaI restriction enzymes (New England Biolabs, MA, USA)
were purchased from Primm srl (Naples, Italy). OVA oligonucleotide
sequences were inserted into the NcoI and XmaI digested pETE2DISP
by ligation with T4 DNA ligase (New England Biolabs) to generate
OVA257–264-E2 and OVA323–339-E2 vectors.The segment of DNA encoding the HIV-1 Gag(p17) protein was
ampliﬁed by polymerase chain reaction (PCR) from pNL4-3Gag vector
(gift of Dr. Ned Landau) using the two oligonucleotides SEQ3: 5′
CATGCCATGGCCGGTGCGA3′ and SEQ4: 5′CATGCCATGGCG-
TAATTTTGGCTGACC3′. Gag(p17) PCR product digested with NcoI
and XmaI restriction enzymes was ligated into the previously digested
pETE2DISP to generate Gag(p17)-E2 vector. Oligonucleotide
sequences SEQ3 and SEQ5: 5′CATGCCCGGGCGTAATTTTGGCTGACC3′
were employed to amplify Gag(p17) cDNA from Gag(p17)-E2 vector
and to introduce NcoI restriction sites at the 5′ and 3′ ends. The Gag
(p17) ampliﬁed cDNA was thus digested and inserted into the NcoI
digested OVA257–264-E2 vector by ligation with T4 DNA ligase to
generate Gag(p17)-OVA257–264-E2 vector.
The BL21 (DE3) E. coli bacteria cells containing circular plasmids
were selected on LB medium plates containing ampicillin (Sigma,
Milan, Italy) and successful construction of the plasmids was
conﬁrmed by DNA sequence analysis (Primm srl.). The construction
of pep23E2 vector, expressing the KDSWTVNDIQKLVGK T helper
epitope from reverse transcriptase of HIV-1 was described previously
(Domingo et al., 2003).
Expression and puriﬁcation of E2 proteins
One liter of LB medium containing 100 μg/ml ampicillin and
30 μg/ml kanamycin (Sigma) was inoculated with 10 ml of an
overnight culture of E. coli BL21 (DE3) co-transformed with OVA257–
264-E2, OVA323–339-E2, Gag(p17)-E2 or Gag(p17)-OVA257–264-E2 and
with pGroEL/ES vectors (De Berardinis et al., 2003; Domingo et al.,
2001, 2003). Cultures were grown at 37 °C until an optical density of
0.6 (600 nm) was obtained. The cells were then heat-induced
overnight at 30 °C with 2 mM Isopropyl β-D-1-thiogalactopyranoside
(IPTG). The Gag(p17)-E2 cell pellet was resuspended in buffer A:
30 mM potassium phosphate pH 6.4, 1 mM phenylmethanesulpho-
nylﬂuoride (PMSF, Sigma) containing 0.1 mg/ml lysozyme (Sigma),
and lysed by sonication. The supernatant containing Gag(p17)-E2
protein was recovered by centrifugation (10,000×g for 1 h). The
proteins that were precipitated between 35% and 40% saturation of
ammonium sulphate were redissolved in buffer A, dialysed against
two changes of the same buffer and applied on a Pharmacia Mono S
HR10/10 HP cation exchange column previously equilibrated with
buffer (20 mM Tris–HCl pH 8.5, 10 mM EDTA, 1 mM PMSF). The Gag
(p17)-E2 protein was eluted with a linear gradient of 0–1 M NaCl in
buffer A at a ﬂow rate of 1 ml/min over 200 ml. The Gag(p17)-
OVA257–264-E2 cell pellet was resuspended in 20 mM potassium
phosphate pH 7.4, 1 mM PMSF (buffer B) containing 0.1 mg/ml
lysozyme and lysed by sonication. The supernatant containing Gag
(p17)-OVA257–264-E2 protein recovered by centrifugation (10,000×g
for 1 h) was applied on a Biorad UNOS12 cation exchange column
previously equilibrated with buffer B. The Gag(p17)-OVA257–264-E2
proteinwas elutedwith a linear gradient of 0–1 MNaCl in buffer B at a
ﬂow rate of 1 ml/min over 200 ml. The fractions containing the E2
proteins were concentrated using a Centriprep30 (Millipore, MA) and
loaded into a Pharmacia Superose-6 gel ﬁltration column previously
equilibrated with 50 mM potassium phosphate. The concentration of
all the E2 constructs was determined by Coomassie dye binding
method (Bradford assay). OVA257–264-E2, OVA323–339-E2 and pep23E2
complexes were puriﬁed using the same condition of E2 wild type (E2
wt) complex puriﬁcation that was previously described (De Berardi-
nis et al., 2003; Domingo et al., 2001, 2003). The hybrid assembly,
pep23E2/Gag(p17)-E2, displaying both Gag(p17) and pep23, was
generated by in vitro denaturation and refolding of mixtures of
E2pep23 and Gag(p17)-E2 according to previously described protocol
(Domingo et al., 2003). Brieﬂy, equimolar quantities of puriﬁed
pep23E2 and Gag(p17)-E2 were mixed and dialyzed against buffer B
containing 5 M GuHCl and 1 mM DTT, followed by dialysis against
buffer B without 5 M GuHCl. Reconstitution of soluble E2 60-mer core
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electron microscopy as previously described (Domingo et al., 2003).
The puriﬁed proteins samples were stored at −80 °C.
Mice
Female C57BL/6xBALB/c F1 hybrid mice (Jackson Laboratory, Bar
Harbor, ME, USA) were housed at the University of Washington, USA.
HHD transgenicmice (Pascolo et al., 1997) expressing a chimeric HLA-
A2.1/H-2-Db MHC class I molecule on a C57BL/6 genetic background,
were kindly provided by Dr. F. A. Lemonnier (Pasteur Institute, Paris,
France). C57BL/6 mice, C57BL/6 OT-II Thy1.1+ or OT-I transgenic
mice were purchased from Charles River Laboratory (Lecco, Italy).
Mice were maintained at the animal facility of CNR, Naples, Italy. All
animals were housed in speciﬁc pathogen free condition in accor-
dance with the standards outlined by the National Institutes of Health
Guide for the Care and Use of Laboratory animals. All experiments
with mice were performed in accordance with European Union Laws
and guidelines, and were approved by our institutional review board.
The animal procedures (i.e. immunization, sacriﬁce) were performed
according to rules approved by the ethical committee. In all case, 8–
12 weeks old age-matched male mice were used for comparative
studies.
Peptides
Overlapping 15-mer peptides encompassing the HIV Gag(p17)
sequence (HIV-1 Con B Gag(p17) 15-mer) were obtained through the
AIDS Research and Reference Reagent Program, Division of AIDS
(NIAID, NIH, USA). The OVA257–264 and OVA323–339 peptides from
chicken ovalbumin were purchased from Primm srl.
Antibody response and ELISA assay
C57BL/6xBALB/c F1 hybrid mice were immunized subcutaneously
(s.c.) with 100 μg of one of the following constructs: E2wt, Gag(p17)-
E2, pep23E2/Gag(p17)-E2. Proteins were administered alone, or in
combination with IFA (Sigma) or CpG-ODN (Cell Sciences, MA).
Plaque forming units (PFU; 107) of recombinant vaccinia virus
expressing HIV Gag (rVV-Gag) in 1× PBS were delivered intraper-
itoneally. Mice were immunized at weeks 0 and 4 and bled by retro-
orbital bleed 2 weeks after each immunization and after 30 weeks
from the ﬁrst immunization. Sera were collected from each mouse
and analyzed by ELISA.
Brieﬂy, 2 μg/ml p55 Gag (Chiron, Emeryville, CA) or E2 proteinwas
diluted in 1× carbonate/bicarbonate buffer (Sigma) and coated onto
96-well plates (MaxiSorpTM, NUNC, NY) overnight at 4 °C. Plates were
blocked in Blotto (1× PBS/5% dry milk/1% normal goat sera) for 1 h at
room temperature then washed ﬁve times and incubated for 5 min in
Wash Buffer (1× PBS/0.1% Triton X-100). Three-fold serial dilutions of
sera were performed with Disruption Buffer (1× PBS/5% FBS/2% BSA/
1% Triton X-100) and incubated in plates for 1 h at room temperature.
After washing, biotin-conjugated goat anti-mouse total IgG (1:1200)
was diluted in Disruption Buffer and applied at 100 μl/well. After
washing, a 1:800 dilution of ExtrAvidin-conjugated horse-radish
peroxidase (HRP, Sigma) was added.
For isotype-speciﬁc ELISAs, HRP-conjugated goat anti-mouse IgG1
(1:4000, Southern Biotech, Birmingham, AL), IgG2a (1:4000, Southern
Biotech) were used, diluted in Disruption Buffer. After a ﬁnal wash,
plates were developedwith 100 μl/well TMB liquid substrate (Sigma).
Reactions were stopped with 1 N H2SO4 (Fisher). Plates were read on
a Molecular Device luminometer at A450–650 using SoftMax pro
(Sunnyvale, CA, USA). The endpoint titer was calculated as the lowest
positive value for each sample that was three-times the average
background of naïve mouse sera included on each plate.Adoptive transfer and in vivo proliferation assay
CD4+ or CD8+ OVA-speciﬁc T cells were obtained from spleen of
OT-II or OT-I mice by negative selection using the CD4+ and CD8+ T
cell isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany).
Enrichment for T cells was conﬁrmed by ﬂow cytometry and was
typically 95–99% pure. The cells were labeled with 5 μM of Carboxy-
ﬂuorescein Succinimidyl ester (CFSE, Sigma) in PBS for 10 min at
37 °C, washed two times with PBS/0.1% BSA and twice with PBS.
CFSE (3×106) labeled OT-I CD8+ or OT-II CD4+ T cells were
injected i.v. into C57BL/6 recipients. Twenty-four hours later, mice
were immunized subcutaneously (s.c.) with 100 μg of each of the
following constructs: OVA257–264-E2, OVA323–339-E2, E2wt or PBS. 5
C57BL/6mice received 500 μg soluble ovalbumin protein plus 50 μg of
poly(I:C) in PBS intra peritoneum. After 3 days, mice were sacriﬁced
and cell suspensions of spleen were isolated and stained with PE
conjugated anti-Vα2 and PE-Cy5-conjugated anti-CD8 or PE-Cy7-
conjugated anti CD4 mAbs (BD Pharmingen, Milan, Italy). The CFSE
ﬂuorescence intensity was then evaluated by multicolor ﬂow
cytometry analysis using a FACS Canto cytometer (Becton Dickinson,
CA, USA).
Intracellular staining
The analysis was performed on 3×106 splenocytes cultured with
10 μg/ml of synthetic peptides (OVA257–264 or OVA323–339) for 5 h in
presence of brefeldin A (Sigma) (10 mg/ml) in a U-bottom 96 well
plate. Cells were cultured in absence of peptide (negative control) or
with 30 ng/ml of Phorbol 12-myristate 13-acetate (PMA), 1 μg/ml of
ionomycin (Sigma) as positive control. The cells were washed and
stained with PE-Cy5 anti-CD8 or PE-Cy7 anti-CD4 mAb on ice for
30 min The cells were treated with LeucopermTM kit (AbD Serotec,
Kidlington, UK) at room temperature for 30 min, stained with PE
conjugated anti-INFγ mAb (eBioscience, Hatﬁeld, UK) according to
manufacture instructions and analyzed by a FACS Canto cytometer
(Becton Dickinson).
Cytotoxicity tests
Cytotoxic activity was assayed in HHD transgenic mice or C57BL/6
mice.
HHD transgenic mice were immunized at days 0 and 14 by
injecting s.c. at the base of the tail 140 μg of double displaying
pep23E2/Gag(p17)-E2 particles in the absence of adjuvants. A control
group of mice received the same amount of E2 wild type particles.
After 7 days mice were sacriﬁced and isolated splenocytes (5×106)
were co-cultured with antigen-pulsed γ-irradiated (10,000 rad)
lipopolysaccaride-blasts (LPS-blasts) (2.5×106) produced from syn-
geneic unimmunized animals. LPS-blast cells consisted of splenocytes
that have been cultured in 25 μg/ml of LPS in RPMI-1640, supple-
mented with 10% FCS, 5×10−5 M 2-ME, 1 mM glutamine, 1 mM
sodium pyruvate, and 7 μg/ml dextran sulphate for 3 days and pulsed
for 3 h with 50 μg/ml of the same E2 preparations used for the
immunization procedure. After 5 days of co-culture, effector cells
were harvested and assayed for cytotoxic activity by the standard 51Cr
release assay, using as target RMA-S HHD cells prepulsed or not with
10 μg/ml synthetic Gag peptide SLYNTVATL. The percentage of
speciﬁc lysis was calculated as described (Domingo et al., 2003).
C57BL/6 mice were immunized twice at days 0 and 14 with 100 μg
of Gag(p17)-OVA257–264-E2 or OVA257–264-E2 particles both display-
ing 5 μg of OVA257–264. A control group of mice received two
administrations of E2 particles in the same conditions as above. All
mice were sacriﬁced and analyzed on day 28. Splenocytes (4×106
cells/well) were stimulated in 24 well plates with LPS-blasts (2×106)
from syngeneic unimmunized mice, which were prepulsed with
OVA257–264 (10 μg/ml) and γ-irradiated, in presence of interleukin 2
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were stimulated in parallel cultures with irradiated BALB/c female
spleen cells bearing the H-2d alloantigen. After 7 days, the speciﬁc CTL
activity of effector cell cultures was determined using the JAM assay
(Matzinger, 1991) with EL4 cells (H-2b) prepulsed or not with 10 μg/
ml of OVA257–264 peptide as target cells. The percentage of speciﬁc
lysis was calculated as described (Matzinger, 1991).
Pentamer staining
Splenocytes were isolated from C57BL/6 mice 14 days after the
second immunization with Gag(p17)-OVA257–264-E2, OVA257–264-E2
or E2 particles and restimulated in vitro with syngeneic LPS-induced
blast cells pulsed with speciﬁc OVA257–264 peptide. After 7 days, the
effector cells (1×106 cells/100 μl) were incubatedwithmouse anti-Fc
receptor mAb (2.4G2 mAb, BD Pharmingen) in ice for 15 min to block
Fc receptors and stained with PE-labeled SIINFEKL Kb pentamer or PE-
labeled SSYSYSSL Kb pentamer (ProImmune, Oxford, UK) in ice for
45 min. FITC-conjugated anti-CD8 mAb (ProImmune) was added for
additional 15 min. The cells were washed, ﬁxed using PBS solution
with 30%methanol and 0.4% paraformaldehyde. Aminimumof 50,000
live, CD8-positive, gated events were acquired and analyzed by ﬂow
cytometry on a FACS Canto (Becton Dickinson).
Statistical analysis
Statistical analyses were performed using the unpaired, two-tailed
Student's t-test. Differences were considered statistically signiﬁcant
when Pb0.05.
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